Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

By afschroeder • October 27, 2026

Powles T, Grande E, Simone G, Gómez de Liaño A, Maruzzo M, Velho PI, Kikuchi E, Vu TQ, Popovic L, Çil T, Gravis G, Radkowski R, Hernández LRN, Cutuli HJ, Bamias A, Bauernhofer T, Pavic M, Choi YJ, Chang CH, Kitamura H, Rosenberg JE, Rowbottom J, Ho S, Gupta A, Drakaki A; VOLGA Investigators. Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer. N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2608323. Epub ahead of print. PMID: 42929692.

Tags: Hematology/Oncology, Publications

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M,[...]

Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review

Han J, Ghamsari F, Yan J, Kim P. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review.[...]

Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology

Law JH, Xie K, Yang J, Kudo M, Muthiah MD, Mehta N, Bhoori S, Pinato DJ, Chee CE, Hatano E, Line PD, Chan SL, Doyle[...]